AstraZeneca Mexico – Ugo de Jacobis, President
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives. The company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). It is also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. In Mexico the company relies on manufacturing capabilities and a staff of 150 people.
Contact details
AstraZeneca S.A. de C.V.
Periférico Sur No. 4305, 5to piso
Col. Jardines de la Montaña, Del. Tlalpan
CP 14210 México DF
MEXICO
Tel: +52 (55) 5374 9600
Website: www.astrazeneca.com/mexico
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
There have been a lot of changes in the Mexican pharmaceutical industry in the last four to five years, most notably the new drug registration process being put in place.…
Andrés Matesanz, general manager at DCS Pharma Mexico, explains how the merger between Dolder and Chemswiss has enlarged the capabilities and the offering of the company in Mexico and showcases…
José Alberto Peña, managing director at Marzam Mexico, showcases the benefits that distributors can offer to the healthcare and life science sector as well as Marzam’s strategy to overcome the…
Carlos Pérez Muguía, CEO at NYCE, showcases the increasing added value brought by this leading Cofepris’ authorized third party (ATP) to the healthcare industry, the future objectives of the company…
Alan Smithers, CEO at IFA Celtics, highlights the obesity as a national healthcare challenge and explains the company’s strategy to enlarge its capabilities to cope with the increasing needs of…
Salomon Rayek, CEO at Sinbiotik, explains how the company managed to adapt its business model to the industry trends and showcases the added value of Sinbiotik when offering high quality,…
Due to economic necessity, the Mexican government is attempting to slash annual spending; an act that could have serious consequences on the country’s ability to provide its citizens with healthcare.…
Francisco Rodriguez, general manager Mexico and Latin America at Mundipharma, provides an overview of the customized market approach that has allowed the company to establish itself as the partner of…
Jorge Romero Castañeda and María Eugenia Mendez, Healthcare & Life Science leader and Strategy & Operations Director at Deloitte respectively, share their expertise about the Healthcare & Life Science sector…
Leonardo Torres, general manager Mexico, Central America & Caribbean of Shire, provides insights into the rapidly progressing integration of Baxalta in Mexico, while he also highlights his key priorities to…
Mario Sturion, the recently appointed general manager of Janssen Mexico, assesses the specific challenges and opportunities of the Mexican health system and explains how a customized market access approach has…
Jaime Cervantes, CEO of Vitalmex, provides insights into the company’s ascendent trajectory, with Vitalmex now looking to leverage its leadership position in the public sector to venture in the private market,…
Alfredo Gutierrez, general director of Anfitriones, documents the company’s heightened focus on creating a true experience that goes beyond traditional business events and congresses, its expanded geographical reach to Colombia…
See our Cookie Privacy Policy Here